Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jürgen Föll

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Frontiers in Oncology|November 19, 2015
Immunostimulation by OX40 Ligand Transgenic Ewing Sarcoma CellsDajana Reuter, Martin S Staege, Caspar D Kühnöl, et al.
Der Ophthalmologe : Zeitschrift Der Deutschen Ophthalmologischen Gesellschaft|January 27, 2021
[Maculopathy in sickle cell disease]Isabel Bachmeier, Christiane Blecha, Jürgen Föll, et al.
Cancer Immunology, Immunotherapy : CII|October 17, 2013
CD137 stimulation and p38 MAPK inhibition improve reactivity in an in vitro model of glioblastoma immunotherapyCaspar Kühnöl, Monique Herbarth, Jürgen Föll, et al.
Ejhaem|January 27, 2025
Defibrotide for the Treatment of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Paediatric Patients Who Did Not Receive Haematopoietic Stem Cell Transplantation: Case Reports of Patients From a German Academic HospitalKatharina Kleinschmidt, Anja Troeger, Jürgen Föll, et al.
Experimental Hematology|April 11, 2008
Gene expression profiles of Hodgkin's lymphoma cell lines with different sensitivity to cytotoxic drugsMartin S Staege, Ursula Banning-Eichenseer, Grit Weissflog, et al.
Hematology/Oncology and Stem Cell Therapy|December 1, 2021
Heparanase wildtype is associated with a reduced incidence of transplant-associated systemic vasculopathiesRaphaela Mueckenhausen, Jürgen Föll, Katharina Kleinschmidt, et al.
BMC Cancer|June 13, 2022
Integrative medicine during the intensive phase of chemotherapy in pediatric oncology in Germany: a randomized controlled trial with 5-year follow upGeorg Seifert, Sarah B Blakeslee, Gabriele Calaminus, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Frontiers in Oncology|November 19, 2015
Immunostimulation by OX40 Ligand Transgenic Ewing Sarcoma CellsDajana Reuter, Martin S Staege, Caspar D Kühnöl, et al.
Der Ophthalmologe : Zeitschrift Der Deutschen Ophthalmologischen Gesellschaft|January 27, 2021
[Maculopathy in sickle cell disease]Isabel Bachmeier, Christiane Blecha, Jürgen Föll, et al.
Cancer Immunology, Immunotherapy : CII|October 17, 2013
CD137 stimulation and p38 MAPK inhibition improve reactivity in an in vitro model of glioblastoma immunotherapyCaspar Kühnöl, Monique Herbarth, Jürgen Föll, et al.
Ejhaem|January 27, 2025
Defibrotide for the Treatment of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Paediatric Patients Who Did Not Receive Haematopoietic Stem Cell Transplantation: Case Reports of Patients From a German Academic HospitalKatharina Kleinschmidt, Anja Troeger, Jürgen Föll, et al.
Experimental Hematology|April 11, 2008
Gene expression profiles of Hodgkin's lymphoma cell lines with different sensitivity to cytotoxic drugsMartin S Staege, Ursula Banning-Eichenseer, Grit Weissflog, et al.
Hematology/Oncology and Stem Cell Therapy|December 1, 2021
Heparanase wildtype is associated with a reduced incidence of transplant-associated systemic vasculopathiesRaphaela Mueckenhausen, Jürgen Föll, Katharina Kleinschmidt, et al.
BMC Cancer|June 13, 2022
Integrative medicine during the intensive phase of chemotherapy in pediatric oncology in Germany: a randomized controlled trial with 5-year follow upGeorg Seifert, Sarah B Blakeslee, Gabriele Calaminus, et al.
Pageof 1